| Literature DB >> 28428784 |
Fangli Lu1,2, Shiguang Huang3.
Abstract
Protozoan parasites such as Plasmodium spp., Leishmania spp., Trypanosoma spp., and Toxoplasma gondii are major causes of parasitic diseases in both humans and animals. The immune system plays a critical role against protozoa, but their immune mechanism remains poorly understood. This highlights the need to investigate the function of immune cells involved in the process of parasite infections and the responses of host immune system to parasite infections. Mast cells (MCs) are known to be central players in allergy and anaphylaxis, and it has been demonstrated that MCs have crucial roles in host defense against a number of different pathogens, including parasites. To date, there are many studies that have examined the interaction of helminth-derived antigens and MCs. As one of the major effector cells, MCs also play an important role in the immune response against some parasitic protozoa, but their role in protozoan infections is, however, less well characterized. Herein, we review the current knowledge about the roles of MCs and their mediators during infections involving highly pathogenic protozoa including Plasmodium spp., Leishmania spp., Trypanosoma spp., and T. gondii. We offer a general review of the data from patients and experimental animal models infected with the aforementioned protozoa, which correlate MCs and MC-derived mediators with exacerbated inflammation and disease progression as well as protection against the parasitic infections in different circumstances. This review updates our current understanding of the roles of MCs during parasitic protozoan infections, and the participation of MCs in parasitic protozoan infections could be of a potential therapeutic target.Entities:
Keywords: Leishmania spp.; Plasmodium spp.; Toxoplasma gondii; Trypanosoma spp.; mast cell
Year: 2017 PMID: 28428784 PMCID: PMC5382204 DOI: 10.3389/fimmu.2017.00363
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
The function of mast cells (MCs) in .
| Parasite | MC/disease | Animal model/patient sample | Mechanism | No involvement | Reference |
|---|---|---|---|---|---|
| In the skin of patients or animals with | Patients with | Significantly increased MC degranulation was correlated with parasitemia and disease severity | Wilainam et al. ( | ||
| Swiss mice exposed to | MCs were observed in the vicinity of sporozoites at 1 h after mosquito bite | Choumet et al. ( | |||
| In the brains of mice with | C57BL/6-WBB6F1- | +/+ mice had lower parasitemia and mortality, with higher tumor necrosis factor levels compared to | Furuta et al. ( | ||
| MC-deficient and basophil-depleted C57BL/6 mice infected with | MCs and basophils were not involved in the development of experimental cerebral malaria | Porcherie et al. ( | |||
| H3R−/− mice infected with | The severity of cerebral malaria was correlated with the increased plasmatic levels of histamine in H3R−/− mice | Beghdadi et al. ( | |||
| Histidine decarboxylase-deficient (HDC−/−) C57BL/6 mice infected with | HDC−/− mice were highly resistant to | Beghdadi et al. ( | |||
| Infected wild-type C57BL/6 mice showed prolonged survival after treatment with antihistamine drugs | |||||
| In the intestines of animals with | Mice infected with | Increased ileal mucosal MCs was positively correlated with elevated parasitemia and ileal interleukin (IL)-4 levels | Chau et al. ( | ||
| Rhesus macaques infected with | Ileal mastocytosis and increased plasma histamine levels were exhibited | Potts et al. ( | |||
| Antihistamine treatment of | MCs and histamine were involved in increased intestinal permeability during | ||||
| In the skin of patients and animals with | Patients with cutaneous leishmaniasis caused by | There was a positive association between the disease duration and MCs count in the skin biopsy | Tuon et al. ( | ||
| Susceptible (BALB/c) and resistant (C57BL/6 and CBA/T6T6) mice infected with | MC numbers were significantly increased in the upper dermis of BALB/c but not in those of C57BL/6 and CBA/T6T6 mice after | Saha et al. ( | |||
| MC-deficient | Significantly enhanced lesion progression and lesional parasite burdens were observed, accompanied by significantly decreased levels of IFN-γ and IL-17A | Dudeck et al. ( | |||
| Dogs infected with | Dermic inflammatory reaction with many degranulated MCs was observed | Calabrese et al. ( | |||
| Skin samples from dogs naturally infected with | Increased number of MCs in the skin was correlated with clinical progression of canine visceral leishmaniasis | Menezes-Souza et al. ( | |||
| MC-deficient | Increased lesion sizes and lesional parasitic loads and reduced locally infiltrating cells were observed in | Maurer et al. ( | |||
| C57BL/6 or BALB/c mice infected with | MCs had no role on lesion size development, parasitic load, and immune cell phenotypes during murine cutaneous leishmaniasis | Paul et al. ( | |||
| In visceral leishmaniasis | Dogs naturally infected with | Lower number of MCs was observed in the lamina propria of gastrointestinal tract of the infected dogs | Pinto et al. ( | ||
| In ocular leishmaniasis | C57BL/10 and BALB/c mice, both susceptible to leishmaniasis, infected with | Many intact MCs were presented in the conjunctiva of both strains of mice at 30 days after infection, while degranulated MCs were observed in the conjunctiva of BALB/c mice at 60 days after infection | Calabrese et al. ( | ||
| In chagasic megacolon | Patients with Chagas disease caused by | The number of tryptase-positive MCs was significantly increased in the lamina propria, muscle layer, or myenteric plexus region | Martins et al. ( | ||
| A greater MC count and more fibrosis were found in the colon musculature with megacolon compared to that without megacolon | Pinheiro et al. ( | ||||
| Patients with megaesophagus had increased numbers of tryptase-positive MCs | Martins et al. ( | ||||
| Swiss mice infected with | Significantly increased number of MCs was observed in the muscular layer of mice with chagasic megacolon | Campos et al. ( | |||
| In Chagas heart disease | CBA mice infected with | Greater parasitemia, higher mortality, myocarditis, and cardiac damage were found in the infected mice treated with MC stabilizer | Meuser-Batista et al. ( | ||
| Patients with chronic Chagas disease | MC chymase density was associated with the intensity of myocardium fibrosis of chronic Chagas disease | Roldão et al. ( | |||
| In | Rats infected with | The levels of MCs in the intestines of | Gould and Castro ( | ||
| In toxoplasmic encephalitis | A patient with meningoencephalitic toxoplasmosis | Systemic cutaneous and gastrointestinal mastocytosis were observed | Koeppel et al. ( | ||
| In ocular | Significantly increased MC number and MC activation were observed in the ocular tissues | Gil et al. ( | |||
| In oral | MC-deficient mice (W/Wv | Rapid lethality of | Cruz et al. ( | ||
| In intraperitoneal | The number of degranulated MCs was significantly higher than that of intact MCs, with a remarkable increase in the influx of neutrophils and Mφ toward the peritoneal cavity | Ferreira et al. ( | |||
| MC-deficient | The influx of Ly6G+ cells toward the peritoneal cavity was significantly reduced compared to control littermates | Del Rio et al. ( | |||
| Kunming outbred mice infected with | Significantly increased parasite burden, tissue inflammation, and Th1 cytokine mRNA levels were detected in the livers and spleens of infected mice treated with an activator of MC release | Huang et al. ( | |||
| Significantly decreased parasite burden and tissue inflammation, and significantly increased Th2 cytokine mRNA levels were detected in the livers and spleens of infected mice treated with an inhibitor of MC release |